Press Releases

Media Inquiries - media@caredxinc.com

Date	Title and Summary	Additional Formats
Toggle Summary Jan 07, 2019	CareDx Reports Preliminary Fourth Quarter and Full Year 2018 Financial Results BRISBANE, Calif. , Jan. 07, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported preliminary financial	View HTML
Toggle Summary Dec 20, 2018	New Data on AlloSure Confirms Its Clinical Utility in Repeat Kidney Transplant Recipients Study published in the American Journal of Transplantation BRISBANE, Calif. , Dec. 20, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic	View HTML
Toggle Summary Dec 17, 2018	CareDx Director Dr. Amy Abernethy Resigns Board Seat to Become Principal Deputy Commissioner of the FDA BRISBANE, Calif. , Dec. 17, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Dr.	View HTML
Toggle Summary Nov 26, 2018	CareDx Strengthens Executive Leadership Team with the Appointment of Reginald Seeto, MB.BS, as President and Chief Business Officer BRISBANE, Calif. , Nov. 26, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Reginald	View HTML
Toggle Summary Nov 26, 2018	CareDx Announces Full Repayment of its Outstanding Debt Recent Equity Financing Leads to Strong, Debt-Free Balance Sheet BRISBANE, Calif. , Nov. 26, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic	View HTML
Toggle Summary Nov 16, 2018	CareDx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares BRISBANE, Calif. , Nov. 16, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced the closing of its	View HTML
Toggle Summary Nov 13, 2018	CareDx Announces Pricing of Public Offering of Common Stock BRISBANE, Calif. , Nov. 13, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced the pricing of an	View HTML
Toggle Summary Nov 13, 2018	CareDx Announces Proposed Public Offering of Common Stock BRISBANE, Calif. , Nov. 13, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that it intends to	View HTML
Toggle Summary Nov 08, 2018	CareDx Reports Third Quarter Results AlloSure launch momentum drives 74% revenue growth BRISBANE, Calif. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for	View HTML
Toggle Summary Nov 07, 2018	CareDx to Participate in Upcoming Investor Conferences BRISBANE, Calif. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Peter Maag ,	View HTML